8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Mar 24, 2026·SEC
Biomea Fusion, Inc.(BMEA)Earnings, Financials & Key Ratios
BMEA•NASDAQ
Price updated Jun 11, 2026
AboutBiomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.Show more
- Revenue$0
- EBITDA-$80M+43.9%
- Net Income-$62M+55.4%
- EPS (Diluted)-1.18+69.2%
- ROE-152.35%-21.5%
- Debt/Equity0.05-68.4%
BMEA Key Insights
Biomea Fusion, Inc. (BMEA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 63.3% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 44.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BMEA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BMEA Price & Volume
Biomea Fusion, Inc. (BMEA) stock price & volume — 10-year historical chart
Loading chart...
BMEA Growth Metrics
Biomea Fusion, Inc. (BMEA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM65.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM75.04%
Return on Capital
10 Years-78.9%
5 Years-91.18%
3 Years-121.35%
Last Year-153.79%
BMEA Recent Earnings
Biomea Fusion, Inc. (BMEA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 11, 2026EPS
$0.17
Est $0.24
+29.2%
Revenue
—
Q2 2026
Mar 24, 2026EPS
$0.64
Est $0.25
-156.0%
Revenue
—
Q4 2025
Nov 4, 2025EPS
$0.27
Est $0.26
-3.8%
Revenue
—
Q3 2025
Aug 5, 2025EPS
$0.51
Est $0.59
+13.6%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.17vs $0.24+29.2% | — |
| Q2 2026 | Mar 24, 2026 | $0.64vs $0.25-156.0% | — |
| Q4 2025 | Nov 4, 2025 | $0.27vs $0.26-3.8% | — |
| Q3 2025 | Aug 5, 2025 | $0.51vs $0.59+13.6% | — |
Based on last 12 quarters of dataView full earnings history →
BMEA Peer Comparison
Biomea Fusion, Inc. (BMEA) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 6.77B | 82.96 | -22.48 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARVN | 457.46M | 7.09 | -5.54 | -0.3% | -247.54% | -44.39% | 0.02 | |
 VYNE | 28.44M | 0.66 | -1.07 | 13.77% | -47.26% | -69.57% | ||
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 ALLO | 458.47M | 1.88 | -2.16 | -100% | -56.45% | 0.26 | ||
 BEAM | 3.02B | 29.41 | -36.31 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 4.84B | 50.23 | -7.76 | -89.97% | -138.57% | -30.88% | 0.21 |
Compare BMEA vs Peers
Biomea Fusion, Inc. (BMEA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BMEA Income Statement
Biomea Fusion, Inc. (BMEA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 132K | 0 | 0 | 0 | 0 | 1.41M | 593K |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | -132K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -1.41M▲ 0% | -593K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | 100% | - | - | - | - | - |
Operating Expenses | 1.2M | 5.2M | 41.67M | 83.63M | 126.14M | 144.07M | 79.9M | 65.98M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 103K | 1.52M | 13.67M | 20.92M | 23.59M | 25.98M | 19.33M | 16.12M |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 1.09M | 3.67M | 28M | 62.71M | 102.55M | 118.08M | 61.98M | 48.2M |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -1.41M | 453K |
Operating Income | -1.2M▲ 0% | -5.33M▼ 345.8% | -41.67M▼ 682.2% | -83.63M▼ 100.7% | -126.14M▼ 50.8% | -144.07M▼ 14.2% | -81.31M▲ 43.6% | -66.57M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -345.77% | -682.19% | -100.72% | -50.82% | -14.22% | 43.56% | - |
EBITDA | -1.2M | -5.2M | -41.42M | -82.94M | -124.62M | -142.32M | -79.9M | -65.55M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -333.64% | -697.27% | -100.26% | -50.25% | -14.2% | 43.86% | 49.93% |
D&A (Non-Cash Add-back) | 0 | 132K | 249K | 691K | 1.51M | 1.75M | 1.41M | 1.02M |
EBIT | -1.2M | -5.32M | -41.67M | -83.63M | -126.14M | -144.07M | -81.31M | -63.83M |
Net Interest Income | 0 | 0 | 100K | 1.81M | 8.88M | 5.64M | 1.86M | 1.84M |
Interest Income | 0 | 0 | 100K | 1.81M | 8.88M | 5.64M | 1.86M | 1.84M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -3K | 3K | 100K | 1.81M | 8.88M | 5.64M | 19.51M | 21.62M |
Pretax Income | -1.2M▲ 0% | -5.32M▼ 344.4% | -41.57M▼ 680.7% | -81.83M▼ 96.9% | -117.25M▼ 43.3% | -138.43M▼ 18.1% | -61.8M▲ 55.4% | -44.95M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -1.2M▲ 0% | -5.32M▼ 344.4% | -41.57M▼ 680.7% | -81.83M▼ 96.9% | -117.25M▼ 43.3% | -138.43M▼ 18.1% | -61.8M▲ 55.4% | -44.95M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -344.41% | -680.75% | -96.86% | -43.29% | -18.06% | 55.36% | 65.05% |
Net Income (Continuing) | -1.2M | -5.32M | -41.57M | -81.83M | -117.25M | -138.43M | -61.8M | -44.95M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.11▲ 0% | -0.50▼ 354.5% | -1.74▼ 248.0% | -2.80▼ 60.9% | -3.44▼ 22.9% | -3.83▼ 11.3% | -1.18▲ 69.2% | -0.62▲ 0% |
EPS Growth % | - | -354.55% | -248% | -60.92% | -22.86% | -11.34% | 69.19% | 75.04% |
EPS (Basic) | -0.11 | -0.50 | -1.74 | -2.80 | -3.44 | -3.83 | -1.18 | - |
Diluted Shares Outstanding | 10.71M | 10.71M | 23.86M | 29.27M | 34.11M | 36.11M | 52.23M | 72.3M |
Basic Shares Outstanding | 10.71M | 10.71M | 23.86M | 29.27M | 34.11M | 36.11M | 52.23M | 72.3M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
BMEA Balance Sheet
Biomea Fusion, Inc. (BMEA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 265K | 62.22M | 176.56M | 117.82M | 179.18M | 68.33M | 58.05M | 46.32M |
Cash & Short-Term Investments | 239K | 61.7M | 173.52M | 113.05M | 176.87M | 58.28M | 55.81M | 44.69M |
Cash Only | 239K | 61.7M | 145.74M | 111.9M | 176.87M | 58.28M | 55.81M | 44.69M |
Short-Term Investments | 0 | 0 | 27.78M | 1.15M | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 4.77M | 2.31M | 10.05M | 2.24M | 1.63M |
Total Non-Current Assets | 0 | 303K | 9.14M | 11.49M | 20.75M | 11.61M | 522K | 67K |
Property, Plant & Equipment | 0 | 291K | 5.69M | 7.99M | 14.87M | 10.62M | 153K | 67K |
Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 1.88M | 0 | 0 | 0 | 369K | 738K |
Other Non-Current Assets | 0 | 12K | 1.58M | 3.5M | 5.87M | 988K | 0 | 0 |
Total Assets | 265K▲ 0% | 62.53M▲ 23494.7% | 185.71M▲ 197.0% | 129.31M▼ 30.4% | 199.93M▲ 54.6% | 79.94M▼ 60.0% | 58.57M▼ 26.7% | 46.38M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 23494.72% | 197% | -30.37% | 54.61% | -60.02% | -26.73% | -138.77% |
Total Current Liabilities | 286K | 1.62M | 4.64M | 19.1M | 22.86M | 21.67M | 11.1M | 9.29M |
Accounts Payable | 271K | 727K | 1.33M | 6.83M | 6.85M | 12.93M | 3.23M | 4.61M |
Days Payables Outstanding | - | 2.01K | - | - | - | - | 837.51 | 3.48K |
Short-Term Debt | 0 | 36K | 0 | 0 | 0 | 0 | 0 | 1.24M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 480K | 636K | 192K | 203K | 6.41M | 3.44M |
Current Ratio | 0.93x | 38.43x | 38.08x | 6.17x | 7.84x | 3.15x | 5.23x | 4.98x |
Quick Ratio | 0.93x | 38.43x | 38.08x | 6.17x | 7.84x | 3.15x | 5.23x | 4.98x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 55.74M | 2.29M | 1.67M | 7.83M | 6.69M | 17.92M | 18.37M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 2.29M | 1.67M | 7.83M | 6.69M | 128K | 12.52M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 55.74M | 0 | 0 | 0 | 0 | 17.79M | 18.37M |
Total Liabilities | 286K | 57.36M | 6.92M | 20.77M | 30.69M | 28.36M | 29.02M | 27.67M |
Total Debt | 0 | 259K | 2.85M | 2.29M | 10.3M | 8.77M | 1.59M | 1.24M |
Net Debt | -239K | -61.44M | -142.89M | -109.61M | -166.57M | -49.51M | -54.22M | -43.45M |
Debt / Equity | - | 0.05x | 0.02x | 0.02x | 0.06x | 0.17x | 0.05x | 0.07x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.66x |
Interest Coverage | - | - | - | - | - | - | - | - |
Total Equity | -21K▲ 0% | 5.17M▲ 24714.3% | 178.78M▲ 3358.8% | 108.54M▼ 39.3% | 169.24M▲ 55.9% | 51.57M▼ 69.5% | 29.55M▼ 42.7% | 18.72M▲ 0% |
Equity Growth % | - | 24714.29% | 3358.75% | -39.29% | 55.92% | -69.53% | -42.7% | -230.54% |
Book Value per Share | -0.00 | 0.48 | 7.49 | 3.71 | 4.96 | 1.43 | 0.57 | 0.26 |
Total Shareholders' Equity | -21K | 5.17M | 178.78M | 108.54M | 169.24M | 51.57M | 29.55M | 18.72M |
Common Stock | 1K | 1K | 3K | 3K | 4K | 4K | 7K | 7K |
Retained Earnings | -2.85M | -8.18M | -49.74M | -131.57M | -248.82M | -387.25M | -449.05M | -461.46M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -10K | -1K | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BMEA Cash Flow Statement
Biomea Fusion, Inc. (BMEA) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.28M | -4.46M | -35.44M | -62.42M | -96.59M | -119.89M | -70.37M | -56.25M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -248.63% | -694.75% | -76.13% | -54.75% | -24.12% | 41.31% | 203.43% |
Net Income | -1.2M | -5.32M | -41.57M | -81.83M | -117.25M | -138.43M | -61.8M | -44.95M |
Depreciation & Amortization | 0 | 132K | 953K | 691K | 1.51M | 0 | 1.41M | 960K |
Stock-Based Compensation | 0 | 0 | 0 | 10.34M | 14.13M | 19.09M | 9.52M | 2.57M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 322K | 6.75M | 715K | 2.69M | 4.59M | -15.8M | -10.99M |
Working Capital Changes | -81K | 411K | -1.57M | 7.67M | 2.33M | -5.15M | -3.7M | -3.84M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -98K | 418K | 640K | 2.96M | 2.56M | 6.09M | -9.7M | -3.1M |
Cash from Investing | 0 | -51K | -33.35M | 27.34M | -2.22M | -362K | 0 | 550K |
Capital Expenditures | 0 | -51K | -3.17M | -1.03M | -3.37M | -362K | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 550K |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 1.44M | 65.97M | 153.19M | 1.24M | 163.8M | 1.67M | 67.9M | 64.53M |
Debt Issued (Net) | 0 | 36K | -36K | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 1.44M | 65.93M | 153.22M | 0 | 161.8M | 1.67M | 67.9M | 64.53M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 1.24M | 2M | 0 | 0 | -3K |
Net Change in Cash | 161K▲ 0% | 61.46M▲ 38071.4% | 84.04M▲ 36.7% | -33.84M▼ 140.3% | 64.99M▲ 292.1% | -118.59M▼ 282.5% | -2.47M▲ 97.9% | 9.2M▲ 0% |
Free Cash Flow | -1.28M▲ 0% | -4.51M▼ 252.6% | -38.61M▼ 756.1% | -63.45M▼ 64.3% | -99.96M▼ 57.6% | -120.26M▼ 20.3% | -70.37M▲ 41.5% | -56.25M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | -252.62% | -756.08% | -64.33% | -57.55% | -20.3% | 41.48% | 50.6% |
FCF per Share | -0.12 | -0.42 | -1.62 | -2.17 | -2.93 | -3.33 | -1.35 | -0.78 |
FCF Conversion (FCF/Net Income) | 1.07x | 0.84x | 0.85x | 0.76x | 0.82x | 0.87x | 1.14x | 1.25x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BMEA Key Ratios
Biomea Fusion, Inc. (BMEA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -206.84% | -45.19% | -56.96% | -84.42% | -125.38% | -152.35% | -196.72% |
| Return on Invested Capital (ROIC) | - | - | -360.26% | -11884.58% | -4566.89% | - | 209.76% |
| Debt / Equity | 0.05x | 0.02x | 0.02x | 0.06x | 0.17x | 0.05x | 0.07x |
| FCF Conversion | 0.84x | 0.85x | 0.76x | 0.82x | 0.87x | 1.14x | 1.25x |
Related:BMEA Dividend History·BMEA Revenue History·BMEA Price History·BMEA P/E History·BMEA Financial Ratios·BMEA Institutional Holders
BMEA SEC Filings & Documents
Biomea Fusion, Inc. (BMEA) SEC filings — annual & quarterly reports (10-K, 10-Q)
BMEA Frequently Asked Questions
Biomea Fusion, Inc. (BMEA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Biomea Fusion, Inc. (BMEA) grew revenue by 0.0% over the past year. Growth has been modest.
Biomea Fusion, Inc. (BMEA) reported a net loss of $45.0M for fiscal year 2025.
Dividend & Returns
Biomea Fusion, Inc. (BMEA) has a return on equity (ROE) of -152.4%. Negative ROE indicates the company is unprofitable.
Biomea Fusion, Inc. (BMEA) had negative free cash flow of $56.2M in fiscal year 2025, likely due to heavy capital investments.